In preclinical studies, the combination approach has been associated with the released of antigens from tumor cells by targeted therapy, which could be more easily acknowledged by antigen‐specific T cells, decreased accumulation of TAMs and Tregs, as well as upregulated expression of PD‐L1 by improved IFNγ release, enhanced CD8+ T cell accumulation, and increased expression of MHC I and II (Figure 3B) [504]. This evidence concerns the gene CD8A and neoplasm.